Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Okuzell lipid is a liposome-based ophthalmic spray developed by Pharmaselect International for the treatment of dry eye disease (Sicca syndrome), particularly evaporative dry eye. The formulation contains a phospholipid complex and sodium hyaluronate (hyaluronic acid). Unlike traditional eye drops, Okuzell lipid is applied to the closed eyelid; upon blinking, the liposomes migrate to the lid margin and integrate into the tear film. This action replenishes and stabilizes the deficient lipid layer, significantly reducing tear evaporation. Simultaneously, the sodium hyaluronate provides long-lasting moisture and lubrication to the ocular surface. The product is preservative-free and is suitable for children, contact lens wearers, and patients who find traditional eye drops difficult to administer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Okuzell lipid.